Skip to main content
TrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor about whether a trial is right for you.

Melanoma Clinical Trials

106 recruiting trials for Melanoma. Eligibility criteria explained in plain English.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.
106
Total Trials
106
Recruiting Now
5
Phase 3 Trials
10
Sponsors

Recruiting Trials

RECRUITINGPhase 1 / Phase 2NCT04787042

Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067

This is a multiphase, multicenter study, which includes a Phase 1a open-label, dose escalation monotherapy study of ST-067 given as an SC injection with or without obinutuzumab...

Sponsor: Simcha IL-18, Inc.Enrolling: 3166 locations
RECRUITINGPhase 2NCT06229340

Leflunomide or Combination of MEK Inhibitor and Hydroxychloroquine for Refractory Patients With RAS Mutations

There is a huge variety of nucleotide substitutions that activate RAS. The search for new "universal" drugs for the RAS pathway that either interfere with RAS upregulation...

Sponsor: N.N. Petrov National Medical Research Center of OncologyEnrolling: 201 location
RECRUITINGPhase 1 / Phase 2NCT07070518

Study of GV20-0251 in Participants With Solid Tumor Malignancies

This is a Phase 1 and Phase 2 study of GV20-0251 being developed for the treatment of participants with advanced solid tumors, who are refractory to approved therapies or other...

Sponsor: GV20 TherapeuticsEnrolling: 3503 locations
RECRUITINGNCT07403630

INTEGRATIVE "MULTI-OMICS" AND FUNCTIONAL PLATFORM FOR THE COMPLETE DIAGNOSTIC CHARACTERIZATION OF TUMORS: THE ITALIAN...

This is a multicenter, experimental preclinical study conducted on primary samples from patients diagnosed with hematological or solid neoplasms defined as high risk. The study...

Sponsor: Azienda Ospedaliero-Universitaria di ParmaEnrolling: 3002 locations
RECRUITINGNCT05461430

Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)

The primary objective of this study, sponsored by Travera Inc. in Massachusetts, is to validate whether the mass response biomarker has potential to predict response of patients...

Sponsor: Travera IncEnrolling: 2001 location
RECRUITINGNCT05429138

Ovarian Reserve and Semen Parameters Evolution During Adjuvant Therapy in Melanoma

Prospective multicentric study including women aged 18 to 37 and men aged 18 to 45 during their visit to centers for the study and storage of human sperm and eggs (CECOS)....

Sponsor: Assistance Publique Hopitaux De MarseilleEnrolling: 8012 locations
RECRUITINGNCT03941379

A Registry of Subjects With Primary Indeterminate Lesions or Choroidal Melanoma

The purpose of this observational research study is to follow participants who have been treated with either bel-sar or received alternate treatment (sham, standard of care...

Sponsor: Aura BiosciencesEnrolling: 50016 locations
RECRUITINGNCT01776905

In Vivo Real-time Detection of Circulating Melanoma Cells

The objective of this clinical trial is to determine whether a Photoacoustic flow cytometry (PAFC)-based prototype device can detect circulating tumor cells (CTCs) in the blood of...

Sponsor: University of ArkansasEnrolling: 751 location
RECRUITINGPhase 2NCT06965231

Perioperative Toripalimab and Endostatin for Stage II Melanoma: A Phase II Trial

This is a Phase II clinical trial to evaluate the efficacy and safety of perioperative toripalimab (anti-PD-1) combined with recombinant human endostatin (Endostar) as...

Sponsor: Fudan UniversityEnrolling: 584 locations
RECRUITINGPhase 3NCT07381972

Photodynamic Therapy Associated With Sonodynamic Therapy for the Treatment of Nodular Basal Cell Carcinoma

Evaluation of a therapeutic protocol based on the combination of photodynamic therapy and sonodynamic therapy, referred to as sonophotodynamic therapy. Since this new protocol is...

Sponsor: University of Sao PauloEnrolling: 1421 location
RECRUITINGPhase 2NCT03646617

Ipilumumab and Nivolumab With or Without Hypofractionated Radiotherapy in Patients With Metastatic Melanoma

The main purpose of this study is to determine the safety of combining ipilimumab and nivolumab with hypofractionated radiotherapy to a single tumor in patients with metastatic...

Sponsor: Abramson Cancer Center at Penn MedicineEnrolling: 543 locations
RECRUITINGPhase 2NCT07288203

A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Melanoma

This is a Phase 2, multicenter, open-label study of lifileucel (tumor-infiltrating lymphocytes \[TIL\]) in participants with previously treated advanced melanoma

Sponsor: Iovance Biotherapeutics, Inc.Enrolling: 1005 locations
RECRUITINGPhase 2NCT07215182

[68Ga]Ga-FAPI Total Body PET/CT for Better and Faster Imaging in Cancer

The goal of this clinical trial is to investigate the use of the tracer \[68Ga\]Ga-FAPI-46 for PET/CT-imaging in response evaluation of patients with advanced stage malignant...

Sponsor: Barbara Malene FischerEnrolling: 202 locations
RECRUITINGPhase 1 / Phase 2NCT07287917

Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors

This study will evaluate the safety, tolerability, and preliminary effectiveness of AMXT 1501 and DFMO when combined with standard treatments for advanced solid tumors. The trial...

Sponsor: Aminex Therapeutics, Inc.Enrolling: 928 locations
RECRUITINGPhase 1NCT04119024

Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic...

This phase I trial studies the side effects and best dose of modified immune cells (IL13Ralpha2 CAR T cells) after a chemotherapy conditioning regimen for the treatment of...

Sponsor: Anusha KalbasiEnrolling: 183 locations
RECRUITINGNCT07049276

The Multicentre Selective Lymphadenectomy Trial - 3

The goal of this clinical trial is to demonstrate that there is no difference (non-inferiorty) in the 2 year recurrence-free survival (RFS) between 2 different surgical approaches...

Sponsor: Melanoma Institute AustraliaEnrolling: 15006 locations
RECRUITINGNCT07148245

Symptoms of Immune Checkpoint Inhibitor Therapy in Cutaneous Melanoma

The introduction of immune checkpoint inhibitors (ICIs) for the treatment of patients with stages IIB to IV cutaneous melanoma resulted in dramatic improvements in mortality rates...

Sponsor: University of California, San FranciscoEnrolling: 3001 location
RECRUITINGNCT05878977

Biomarkers in Immunotherapy of Melanoma

Background: Immunotherapy has been successful in treating advanced melanoma, but a large proportion of patients do not respond to the treatment with immune checkpoint inhibitors...

Sponsor: Institute of Oncology LjubljanaEnrolling: 1501 location
RECRUITINGPhase 1NCT06326411

A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors

This is a two-part Phase 1, open label, multi-center, single arm, non-randomized, multiple dose, safety, pharmacokinetic (PK) and preliminary efficacy study of single agent...

Sponsor: Nested Therapeutics, IncEnrolling: 23020 locations
RECRUITINGNCT02280889

Quality of Life and Stigmatization in Children With Congenital Melanocytic Nevi Before and After Nevus Excision

Congenital melanocytic nevi (CMN) are a quite common congenital disorder. Over years, surgical excision was proposed to the patients because transformation into a malignant skin...

Sponsor: University Children's Hospital, ZurichEnrolling: 1001 location
RECRUITINGNCT05856565

Generation of an Artificial Intelligence Algorithm Based on the Analysis of Melanoma Peri-scar Dermatoheliosis, as a...

In the last decade, the advent of immunotherapies with inhibitors of immune checkpoints, such as anti-PD-1 and anti-CTLA-4, has revolutionized the treatment of advanced or...

Sponsor: Nantes University HospitalEnrolling: 7004 locations
RECRUITINGNCT06384053

Skin Cancer and Hyperthermia and Radiotherapy

The SAHARA trial assesses wether combining ultrahypofractionated accelerated radiotherapy (RT) with hyperthermia is as effective as standard hypofractionated high-dose radiation...

Sponsor: Kantonsspital Winterthur KSWEnrolling: 1004 locations
RECRUITINGPhase 1NCT06839105

A Clinical Study to Evaluate the Safety and Tolerability of AWT020 in Patients With Advanced Malignancies

The purpose of this phase I clinical study was to evaluate the safety and tolerability of AWT020 monotherapy and combination with other antitumor therapies in patients with...

Sponsor: Shanghai Junshi Bioscience Co., Ltd.Enrolling: 21413 locations
RECRUITINGPhase 1NCT06781983

Safety and Tolerability of IPH4502 in Patients With Advanced Solid Tumors

This is a first-in-human, open-label, multicenter, Phase 1 study to evaluate the safety, tolerability and preliminary efficacy of IPH4502 and to determine the recommended Phase 2...

Sponsor: Innate PharmaEnrolling: 1457 locations
RECRUITINGNCT05839912

Excision of Lymph Node Trial (EXCILYNT) (Mel69)

The purpose of this study is to find out if removing only the cancerous lymph node (known as a lymph node excision) is effective at preventing cancer from coming back in the same...

Sponsor: Craig L Slingluff, JrEnrolling: 667 locations
RECRUITINGPhase 2NCT06365619

Neoadjuvant Ipilimumab/Nivolumab for Patients With Recurrent, High Risk, Resectable Melanoma

The goal of this clinical trial is to study the impact of Neoadjuvant ipilimumab and nivolumab for melanoma patients that had recurrence during or after adjuvant anti-PD-1...

Sponsor: University of UtahEnrolling: 251 location
RECRUITINGNCT07327489

Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies

This study will collect tumor specimens with correlated clinical and demographic data from patients who are undergoing a biopsy or similar procedure to obtain tumor tissue as a...

Sponsor: ElephasEnrolling: 20008 locations
RECRUITINGPhase 1NCT06398418

R-5780-01 In Combination With PD-1 Checkpoint Inhibitors (Checkpoint Protein on Immune Cells Called T Cells) in...

The goal of this study is determine the safety and tolerability of orally taken probiotic (R-5780) in patients currently on a PD-1 Pathway Checkpoint Inhibitor (checkpoint protein...

Sponsor: Rise Therapeutics LLCEnrolling: 331 location
RECRUITINGPhase 1NCT05968690

Naltrexone and Propranolol Combined With Immunotherapy

Various forms of stress can promote cancer development and growth and negatively impact the immune system's response to tumors. Beta-adrenergic and opioid receptors co-exist in...

Sponsor: Sarah WeissEnrolling: 121 location
RECRUITINGPhase 1NCT07260591

VSV-02 Compassionate Use in Advanced Solid Tumors

This is a clinical study for patients with advanced solid tumors who have limited or no effective treatment options available. The study aims to evaluate a new investigational...

Sponsor: The First Affiliated Hospital of Xinxiang Medical CollegeEnrolling: 61 location
RECRUITINGPhase 1 / Phase 2NCT06265025

GM103 Intratumoral Injection in Patients With Locally Advanced, Unresectable, Refractory and/or Metastatic Solid Tumors

The purpose of this study is to measure safety, tolerability, and preliminary antitumor efficacy of GM103 administered alone and in combination with pembrolizumab in patients with...

Sponsor: GeneMedicine Co., Ltd.Enrolling: 1254 locations
RECRUITINGPhase 1NCT07160335

A Phase I Clinical Study to Evaluate the PK Profile, Efficacy, Safety and Immunogenicity of HLX17 vs. Keytruda® in...

This is a multicenter, randomized, double-blind, parallel-controlled phase I clinical study to evaluate the similarity in PK profile, efficacy, safety, and immunogenicity of HLX17...

Sponsor: Shanghai Henlius BiotechEnrolling: 17420 locations
RECRUITINGPhase 3NCT05868707

OH2 Injection in Melanoma

To evaluate the efficacy of OH2 injection in patients with unresectable or metastatic melanoma who have failed at least second-line standard therapy, using investigator-selected...

Sponsor: Binhui Biopharmaceutical Co., Ltd.Enrolling: 34020 locations
RECRUITINGPhase 1 / Phase 2NCT02332668

A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma...

Researchers are looking for new ways to treat children with different types of melanoma (skin cancer), solid tumors, and lymphomas (blood cancers) that are any of these: *...

Sponsor: Merck Sharp & Dohme LLCEnrolling: 37017 locations
RECRUITINGPhase 2NCT04126876

A Randomized Controlled Phase II Trial With Intradermal IMO-2125 in Pathological Tumor Stage (p) T3-4 cN0M0 Melanoma

Currently, there is no widely used adjuvant treatment available to improve survival after surgical excision of a primary melanoma. In a previous study, loco-regional and systemic...

Sponsor: A.J.M. van den EertweghEnrolling: 2141 location
RECRUITINGNCT03888950

Interim FDG PET-CT in Melanoma Metastatic Patient's Treated by Anti-PD1 Therapy

The objective of this study is to assess whether FDG (18F-2-fluoro-2-deoxy-D-glucose fluorodeoxyglucose) PET-CT could be an early predictive method of therapeutic response to...

Sponsor: Centre Hospitalier Universitaire de NiceEnrolling: 201 location
RECRUITINGNCT04611568

War on Melanoma™ Public Health & Education Campaign

This trial studies how well a health educational campaign works in increasing early detection of melanoma in Oregon. The health educational campaign may provide information to...

Sponsor: OHSU Knight Cancer InstituteEnrolling: 750001 location
RECRUITINGPhase 2NCT05969860

At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer

This clinical trial studies the effect of cancer directed therapy given at-home versus in the clinic for patients with cancer that may have spread from where it first started to...

Sponsor: Mayo ClinicEnrolling: 2202 locations
RECRUITINGEarly Phase 1NCT06472661

FUSA With Intratumoral PolyICLC in Regionally Advanced Resectable Melanoma

This study is for adult patients with advanced melanoma who are receiving immunotherapy and who are planning on having surgery for their cancer. All participants in this study...

Sponsor: University of VirginiaEnrolling: 111 location
RECRUITINGPhase 2NCT05524935

Olaparib in Combination With Pembrolizumab for Advanced Uveal Melanoma

This is a prospective phase II multi-center trial of the combination of the PARP inhibitor olaparib with the immune checkpoint inhibitor pembrolizumab in advanced uveal melanoma.

Sponsor: H. Lee Moffitt Cancer Center and Research InstituteEnrolling: 371 location
RECRUITINGNCT07364474

Immune Response to Percutaneous Hepatic Perfusion With Melphalan for Ocular Melanoma Metastatic to the Liver

This study seeks to better understand the liver's immune response to receiving chemotherapy agent melphalan through Percutaneous Hepatic Perfusion (PHP) for patients with Uveal...

Sponsor: Massachusetts General HospitalEnrolling: 101 location
RECRUITINGPhase 2 / Phase 3NCT06624644

A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma

The goal of this clinical trial is to understand if a new drug called LNS8801 can safely treat patients with melanoma. The primary question to be answered is what is the average...

Sponsor: Linnaeus Therapeutics, Inc.Enrolling: 1357 locations
RECRUITINGPhase 1NCT04903119

Nilotinib Plus Dabrafenib/Trametinib or Encorafenib/Binimetinib in Metastatic Melanoma

This is a phase 1 dose-escalation study of nilotinib in combination with fixed-dose dabrafenib and trametinib regimen for patients with metastatic or unresectable melanoma...

Sponsor: Rina PlattnerEnrolling: 304 locations
RECRUITINGNCT02402244

Project: Every Child for Younger Patients With Cancer

This study gathers health information for the Project: Every Child for younger patients with cancer. Gathering health information over time from younger patients with cancer may...

Sponsor: Children's Oncology GroupEnrolling: 7500020 locations
RECRUITINGNCT05377957

Prospective Registration Of Patient Data and Quality of Life in Eye Melanoma Patients

PROQEM is a prospective cohort study among patients diagnosed with uveal melanoma to assess quality of life before and in the first five years after treatment.

Sponsor: Leiden University Medical CenterEnrolling: 5001 location
RECRUITINGPhase 1NCT03093909

Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases

Any time the words "you," "your," "I," or "me" appear, it is meant to apply to the potential participant. The goal of this clinical research study is to find the highest...

Sponsor: M.D. Anderson Cancer CenterEnrolling: 441 location
RECRUITINGPhase 1NCT05130255

GD2-SADA:177Lu-DOTA Complex in Patients With Solid Tumors Known to Express GD2

Patients with Small Cell Lung Cancer, High Risk Neuroblastoma, Sarcoma and Malignant Melanoma will be treated with GD2-SADA:177Lu-DOTA complex(The IMP is a two-step...

Sponsor: Y-mAbs TherapeuticsEnrolling: 608 locations
RECRUITINGPhase 3NCT06743126

SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic...

This clinical trial is a prospective, multicenter, open-label, randomized, actively controlled, parallel-group Phase 3 clinical trial to evaluate the efficacy, safety and...

Sponsor: Immatics US, Inc.Enrolling: 36020 locations
RECRUITINGPhase 1NCT03743298

Safety of AV-MEL-1 With Anti-PD-1 Therapy in Metastatic Melanoma

This is an open label, single-arm, phase IB treatment study to determine the safety of administering anti-PD1 monoclonal antibodies with AV-MEL-1 and to get some suggestion of...

Sponsor: Aivita Biomedical, Inc.Enrolling: 202 locations
RECRUITINGPhase 1 / Phase 2NCT06249048

Phase 1/2 Study of Intratumoral Injection of STX-001 in Advanced Solid Tumors as Monotherapy or in Combination With...

Phase 1/2, Open-label, Multi-center, First-in-human Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of STX-001 Delivered by...

Sponsor: Strand Therapeutics Inc.Enrolling: 1087 locations

Showing 50 of 106 trials.Search all Melanoma trials